Catalyst Pharmaceuticals, Inc. (CPRX)
USD 21.34
(-7.52%)
USD 21.34
(-7.52%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 86.81 Million USD | 17.79% |
| 2022 | 101.83 Million USD | 94.4% |
| 2021 | 52.38 Million USD | 26.83% |
| 2020 | 41.3 Million USD | 29.79% |
| 2019 | 31.82 Million USD | 190.16% |
| 2018 | -35.25 Million USD | -90.86% |
| 2017 | -18.49 Million USD | 8.3% |
| 2016 | -18.02 Million USD | 1.45% |
| 2015 | -20.46 Million USD | -50.79% |
| 2014 | -13.57 Million USD | -61.58% |
| 2013 | -8.39 Million USD | -32.25% |
| 2012 | -6.35 Million USD | -11.04% |
| 2011 | -6.34 Million USD | -43.04% |
| 2010 | -3.99 Million USD | 44.81% |
| 2009 | -7.21 Million USD | 33.29% |
| 2008 | -10.53 Million USD | -116.73% |
| 2007 | -5.01 Million USD | -72.96% |
| 2006 | -2.72 Million USD | -59.13% |
| 2005 | -1.82 Million USD | -235.57% |
| 2004 | -542.59 Thousand USD | -26.59% |
| 2003 | -428.61 Thousand USD | -67.46% |
| 2002 | -255.94 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 63.75 Million USD | 48.39% |
| 2024 Q1 | 36.55 Million USD | -28.09% |
| 2023 Q4 | 50.83 Million USD | 277.62% |
| 2023 FY | - USD | 17.79% |
| 2023 Q2 | 55.26 Million USD | 31.16% |
| 2023 Q3 | -28.62 Million USD | -151.78% |
| 2023 Q1 | 42.14 Million USD | 36.81% |
| 2022 Q3 | 25.65 Million USD | -10.32% |
| 2022 Q4 | 30.8 Million USD | 20.06% |
| 2022 Q1 | 17.4 Million USD | 36.56% |
| 2022 Q2 | 28.6 Million USD | 64.4% |
| 2022 FY | - USD | 94.4% |
| 2021 Q2 | 15.86 Million USD | 60.33% |
| 2021 Q1 | 9.89 Million USD | 14.85% |
| 2021 Q4 | 12.74 Million USD | -9.21% |
| 2021 FY | - USD | 26.83% |
| 2021 Q3 | 14.03 Million USD | -11.56% |
| 2020 Q3 | 11.79 Million USD | 7.5% |
| 2020 Q1 | 10.77 Million USD | 34.59% |
| 2020 FY | - USD | 29.79% |
| 2020 Q2 | 10.96 Million USD | 1.8% |
| 2020 Q4 | 8.61 Million USD | -26.92% |
| 2019 Q3 | 13.85 Million USD | 26.32% |
| 2019 FY | - USD | 190.16% |
| 2019 Q1 | -987.76 Thousand USD | 93.35% |
| 2019 Q2 | 10.96 Million USD | 1210.14% |
| 2019 Q4 | 8 Million USD | -42.2% |
| 2018 Q2 | -6.33 Million USD | -6.93% |
| 2018 Q1 | -5.92 Million USD | -7.5% |
| 2018 FY | - USD | -90.86% |
| 2018 Q4 | -14.84 Million USD | -81.61% |
| 2018 Q3 | -8.17 Million USD | -29.0% |
| 2017 Q4 | -5.51 Million USD | -28.36% |
| 2017 FY | - USD | 8.3% |
| 2017 Q2 | -4.37 Million USD | -2.55% |
| 2017 Q1 | -4.26 Million USD | 3.43% |
| 2017 Q3 | -4.29 Million USD | 1.94% |
| 2016 Q4 | -4.42 Million USD | -16.42% |
| 2016 Q1 | -6.95 Million USD | -5.72% |
| 2016 Q3 | -3.79 Million USD | 23.41% |
| 2016 FY | - USD | 1.45% |
| 2016 Q2 | -4.95 Million USD | 28.73% |
| 2015 Q4 | -6.58 Million USD | -19.06% |
| 2015 Q1 | -3.1 Million USD | 30.23% |
| 2015 Q2 | -5.23 Million USD | -68.56% |
| 2015 FY | - USD | -50.79% |
| 2015 Q3 | -5.52 Million USD | -5.67% |
| 2014 Q2 | -2.76 Million USD | 12.85% |
| 2014 FY | - USD | -61.58% |
| 2014 Q4 | -4.44 Million USD | -39.21% |
| 2014 Q3 | -3.19 Million USD | -15.74% |
| 2014 Q1 | -3.16 Million USD | 21.43% |
| 2013 FY | - USD | -32.25% |
| 2013 Q1 | -1.66 Million USD | 43.18% |
| 2013 Q2 | -2.14 Million USD | -29.46% |
| 2013 Q3 | -563.46 Thousand USD | 73.78% |
| 2013 Q4 | -4.03 Million USD | -615.46% |
| 2012 Q4 | -2.92 Million USD | -5004.36% |
| 2012 Q1 | -1.63 Million USD | 19.26% |
| 2012 Q3 | 59.57 Thousand USD | 103.24% |
| 2012 FY | - USD | -11.04% |
| 2012 Q2 | -1.84 Million USD | -12.56% |
| 2011 Q4 | -2.02 Million USD | -80.36% |
| 2011 FY | - USD | -43.04% |
| 2011 Q2 | -1.37 Million USD | 9.01% |
| 2011 Q1 | -1.51 Million USD | -108.45% |
| 2011 Q3 | -1.12 Million USD | 18.37% |
| 2010 FY | - USD | 44.81% |
| 2010 Q3 | -902.23 Thousand USD | 32.0% |
| 2010 Q2 | -1.32 Million USD | -27.13% |
| 2010 Q1 | -1.04 Million USD | 10.23% |
| 2010 Q4 | -725.74 Thousand USD | 19.56% |
| 2009 Q2 | -1.76 Million USD | 42.01% |
| 2009 Q3 | -1.28 Million USD | 27.03% |
| 2009 Q4 | -1.16 Million USD | 9.52% |
| 2009 FY | - USD | 33.29% |
| 2009 Q1 | -3.03 Million USD | 19.74% |
| 2008 Q4 | -3.78 Million USD | -30.16% |
| 2008 Q3 | -2.9 Million USD | -18.37% |
| 2008 Q2 | -2.45 Million USD | -43.11% |
| 2008 Q1 | -1.71 Million USD | -51.19% |
| 2008 FY | - USD | -116.73% |
| 2007 FY | - USD | -72.96% |
| 2007 Q3 | -947.01 Thousand USD | 33.98% |
| 2007 Q4 | -1.13 Million USD | -19.84% |
| 2007 Q2 | -1.43 Million USD | 4.06% |
| 2007 Q1 | -1.49 Million USD | -69.04% |
| 2006 Q3 | -1.34 Million USD | -297.09% |
| 2006 Q2 | -337.47 Thousand USD | -1.22% |
| 2006 FY | - USD | -59.13% |
| 2006 Q1 | -333.41 Thousand USD | 74.77% |
| 2006 Q4 | -884.41 Thousand USD | 34.0% |
| 2005 Q3 | -241.85 Thousand USD | 63.4% |
| 2005 FY | - USD | -235.57% |
| 2005 Q4 | -1.32 Million USD | -446.48% |
| 2005 Q2 | -660.83 Thousand USD | 0.0% |
| 2005 Q1 | -660.83 Thousand USD | -389.67% |
| 2004 Q3 | -134.95 Thousand USD | 0.0% |
| 2004 Q2 | -134.95 Thousand USD | 0.0% |
| 2004 FY | - USD | -26.59% |
| 2004 Q1 | -134.95 Thousand USD | 0.0% |
| 2004 Q4 | -134.95 Thousand USD | 0.0% |
| 2003 FY | - USD | -67.46% |
| 2002 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbCellera Biologics Inc. | -192.15 Million USD | 145.177% |
| Alkermes plc | 495.04 Million USD | 82.464% |
| Agenus Inc. | -145.92 Million USD | 159.491% |
| Aptorum Group Limited | -9.59 Million USD | 1004.386% |
| Ardelyx, Inc. | -55.35 Million USD | 256.831% |
| Dyadic International, Inc. | -8.22 Million USD | 1154.857% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | 29932.302% |
| Lantern Pharma Inc. | -15.78 Million USD | 649.906% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 535.97% |
| Novavax, Inc. | -487.39 Million USD | 117.812% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 222.229% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 210.598% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 583.001% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 970.907% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 251.304% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 122.847% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 460.038% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | -16310.586% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 155.226% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 216.036% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 530.636% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 465.755% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 476.494% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 171.097% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 133.617% |
| AlloVir, Inc. | -190.14 Million USD | 145.655% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 149.417% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 396.712% |
| Bicycle Therapeutics plc | -183.4 Million USD | 147.335% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 152.479% |
| ChromaDex Corporation | -3.89 Million USD | 2329.379% |
| Chimerix, Inc. | -92.97 Million USD | 193.372% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 295.361% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 177.143% |
| CRISPR Therapeutics AG | -202.7 Million USD | 142.828% |
| Precision BioSciences, Inc. | -32.04 Million USD | 370.932% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 150.405% |
| Fortress Biotech, Inc. | -133.64 Million USD | 164.958% |
| Fortress Biotech, Inc. | -133.64 Million USD | 164.958% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 212.243% |
| ImmuCell Corporation | -2.5 Million USD | 3566.826% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 166.563% |
| Immix Biopharma, Inc. | -16.13 Million USD | 638.014% |
| Incyte Corporation | 919.42 Million USD | 90.558% |
| Innoviva, Inc. | 248.96 Million USD | 65.13% |
| IO Biotech, Inc. | -91.22 Million USD | 195.159% |
| Jaguar Health, Inc. | -33.13 Million USD | 362.027% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 157.047% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 14.662% |
| ContextLogic Inc. | -324 Million USD | 126.794% |
| MiMedx Group, Inc. | 40.51 Million USD | -114.261% |
| MEI Pharma, Inc. | 26.38 Million USD | -229.083% |
| NextCure, Inc. | -59.03 Million USD | 247.042% |
| Onconetix, Inc. | -36.7 Million USD | 336.502% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | -3784.206% |
| Opthea Limited | -200.01 Million USD | 143.402% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 3254.987% |
| Vaxcyte, Inc. | -464.88 Million USD | 118.674% |
| PDS Biotechnology Corporation | -40.08 Million USD | 316.57% |
| Precigen, Inc. | -89.22 Million USD | 197.295% |
| Pharming Group N.V. | 9.87 Million USD | -778.931% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 154.582% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 481.39% |
| PureTech Health plc | -11.62 Million USD | 846.641% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 611.23% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 137.179% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 460.038% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 199.297% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 399.734% |
| Acelyrin, Inc. | -381.52 Million USD | 122.754% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | 673850.416% |
| Summit Therapeutics Inc. | 1 Million USD | -8572.527% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 360.025% |
| Senti Biosciences, Inc. | -61.33 Million USD | 241.535% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 177.301% |
| Elevation Oncology, Inc. | -41.46 Million USD | 309.352% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 380.909% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 1519.298% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | 27144.237% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 367.501% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 1133.969% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 247.665% |
| Seer, Inc. | -97.88 Million USD | 188.688% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 239.576% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 232.811% |
| ESSA Pharma Inc. | -26.45 Million USD | 428.146% |
| GlycoMimetics, Inc. | -39.12 Million USD | 321.901% |
| GT Biopharma, Inc. | 5.97 Million USD | -1351.948% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 142.0% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | 1364.007% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 252.962% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 269.492% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 978.05% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 116.078% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 1361.069% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 285.25% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 136.688% |
| Aptose Biosciences Inc. | -52.26 Million USD | 266.09% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 180.573% |
| Soligenix, Inc. | -7.85 Million USD | 1205.484% |
| Century Therapeutics, Inc. | -121.2 Million USD | 171.622% |
| Kura Oncology, Inc. | -164.95 Million USD | 152.628% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 208.382% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 960.718% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | 9164.265% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 2114.667% |
| Autolus Therapeutics plc | -156.77 Million USD | 155.375% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 202.546% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 225.813% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 535.497% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 145.866% |
| GRI Bio, Inc. | -10.89 Million USD | 896.587% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 2022.442% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 170.863% |
| IGM Biosciences, Inc. | -253.35 Million USD | 134.265% |
| INmune Bio, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 183.64% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 327.655% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 666.255% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 651.424% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 252.717% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 181.055% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 132.636% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 144.763% |
| Verastem, Inc. | -83.16 Million USD | 204.384% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 271.66% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 154.865% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 176.091% |
| Histogen Inc. | -10.5 Million USD | 926.545% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 707.94% |
| Surrozen, Inc. | -41.13 Million USD | 311.062% |
| Organovo Holdings, Inc. | -14.8 Million USD | 686.33% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -2706853.539% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 247.858% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 269.244% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 503.046% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 1141.16% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 152.276% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 276.238% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 459.232% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 676.631% |
| Apollomics, Inc. | -171.74 Million USD | 150.546% |
| Amarin Corporation plc | -50.9 Million USD | 270.549% |
| Mesoblast Limited | -61.33 Million USD | 241.547% |
| Turnstone Biologics Corp. | -56.23 Million USD | 254.376% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 160.622% |
| Synaptogenix, Inc. | -8.3 Million USD | 1144.983% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 665.956% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 237.694% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 1911.805% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | -20134.058% |
| Exelixis, Inc. | 196.6 Million USD | 55.844% |
| Better Therapeutics, Inc. | -38.26 Million USD | 326.888% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 161.391% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 117.53% |
| NLS Pharmaceutics AG | -11.79 Million USD | 835.966% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | -35015.85% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 394.218% |
| Gritstone bio, Inc. | -126.86 Million USD | 168.43% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 233.588% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 2270.329% |
| Avid Bioservices, Inc. | -11.48 Million USD | 856.136% |
| Insmed Incorporated | -654.73 Million USD | 113.259% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | 3958.793% |
| MediWound Ltd. | -4.89 Million USD | 1874.208% |
| OmniAb, Inc. | -49.73 Million USD | 274.563% |
| Alector, Inc. | -142.89 Million USD | 160.754% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 201.613% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 266.472% |
| Zai Lab Limited | -366.57 Million USD | 123.682% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 129.87% |
| Aura Biosciences, Inc. | -83.69 Million USD | 203.723% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 138.54% |
| Immunic, Inc. | -99.11 Million USD | 187.59% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 165.931% |
| Veracyte, Inc. | -49.4 Million USD | 275.701% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 1328.947% |
| FibroGen, Inc. | -261.4 Million USD | 133.21% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 879.212% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 1339.936% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 563.817% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 94.011% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 441.484% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | -117.628% |
| TG Therapeutics, Inc. | 26.1 Million USD | -232.613% |
| Galecto, Inc. | -37.51 Million USD | 331.381% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 326.871% |
| Fortrea Holdings Inc. | 167.3 Million USD | 48.11% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 164.65% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 406.637% |
| XBiotech Inc. | -35.76 Million USD | 342.722% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 233.588% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 233.045% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 183.109% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 438.158% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 312.426% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 116.809% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 254.963% |
| Vaxxinity, Inc. | -56.05 Thousand USD | 154980.377% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 174.622% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 491.582% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 136.931% |
| NexImmune, Inc. | -28.16 Million USD | 408.199% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 1671.102% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 836.177% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 98.135% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 441.887% |
| Scopus BioPharma Inc. | -11.71 Million USD | 841.15% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 168.983% |
| Ainos, Inc. | -8.77 Million USD | 1089.525% |
| Pluri Inc. | -20.22 Million USD | 529.231% |
| Prothena Corporation plc | -190.1 Million USD | 145.665% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 167.717% |
| Celularity Inc. | -183.94 Million USD | 147.194% |
| Rallybio Corporation | -72.37 Million USD | 219.951% |
| Cue Biopharma, Inc. | -46.05 Million USD | 288.509% |
| MeiraGTx Holdings plc | -57.05 Million USD | 252.163% |
| Omeros Corporation | -163.61 Million USD | 153.06% |
| Humacyte, Inc. | -96.45 Million USD | 190.0% |
| Immunocore Holdings plc | -59.64 Million USD | 245.538% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 548.131% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 456.298% |
| Blueprint Medicines Corporation | -474.61 Million USD | 118.291% |
| CalciMedica, Inc. | -34.18 Million USD | 353.918% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 218.541% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 169.175% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 151.535% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 134.396% |
| Pulmatrix, Inc. | -12.64 Million USD | 786.478% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 363.338% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 198.129% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 117.146% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 185.77% |
| Cytokinetics, Incorporated | -456.68 Million USD | 119.009% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 360.126% |
| Nutriband Inc. | -5.12 Million USD | 1794.959% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 300.619% |
| Vor Biopharma Inc. | -114.37 Million USD | 175.904% |
| Roivant Sciences Ltd. | -996.51 Million USD | 108.712% |
| Evogene Ltd. | -23.2 Million USD | 474.125% |
| ProKidney Corp. | -147.66 Million USD | 158.788% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 234.519% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | 56784.667% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 115.352% |
| CorMedix Inc. | -48.88 Million USD | 277.577% |
| BioLineRx Ltd. | -57.06 Million USD | 252.139% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 177.679% |
| Galectin Therapeutics Inc. | -202 Thousand USD | 43076.238% |
| Atai Life Sciences N.V. | -36.31 Million USD | 339.079% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 209.174% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 206.763% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 131.51% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 382.407% |
| MediciNova, Inc. | -9.87 Million USD | 978.667% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 168.931% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 5773.242% |
| GeoVax Labs, Inc. | -26.66 Million USD | 425.519% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 138.585% |
| Biomea Fusion, Inc. | -124.62 Million USD | 169.661% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 126.28% |
| Mereo BioPharma Group plc | -26.05 Million USD | 433.175% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 145.609% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 137.754% |
| Absci Corporation | -95.45 Million USD | 190.944% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 389.132% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 181.043% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 137.182% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 479.838% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 141.769% |
| Allakos Inc. | -189.91 Million USD | 145.711% |
| Imunon, Inc. | -19.87 Million USD | 536.718% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 180.017% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 19.859% |
| BioAtla, Inc. | -122.24 Million USD | 171.017% |
| NLS Pharmaceutics AG | -11.79 Million USD | 835.966% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 650.803% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 128.909% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 309.453% |
| XOMA Corporation | -39.36 Million USD | 320.548% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 187.464% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 173.788% |
| aTyr Pharma, Inc. | -52.17 Million USD | 266.377% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 203.576% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 158.408% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 137.01% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 735.846% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 1179.442% |
| Akari Therapeutics, Plc | -16.8 Million USD | 616.677% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -45903.837% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 80.792% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 1458.853% |
| UroGen Pharma Ltd. | -63.83 Million USD | 236.003% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 227.824% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 1295.262% |
| Orgenesis Inc. | -60.71 Million USD | 242.976% |
| Entera Bio Ltd. | -8.8 Million USD | 1086.052% |
| GH Research PLC | -41.15 Million USD | 310.949% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 440.186% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 205.568% |
| Xencor, Inc. | -125.87 Million USD | 168.967% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | 6185.472% |
| Replimune Group, Inc. | -230.19 Million USD | 137.712% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 530.666% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 893.383% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 1458.853% |
| Portage Biotech Inc. | -18.19 Million USD | 577.015% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 5773.242% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 183.007% |
| OncoCyte Corporation | -23.12 Million USD | 475.436% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 868.223% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 857.731% |
| Purple Biotech Ltd. | -22.22 Million USD | 490.605% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 1454.321% |
| scPharmaceuticals Inc. | -46.06 Million USD | 288.472% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 587.443% |
| HilleVax, Inc. | -132.46 Million USD | 165.535% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 916.439% |
| Tharimmune, Inc. | -9.3 Million USD | 1033.203% |
| Genprex, Inc. | -31.06 Million USD | 379.493% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 146.293% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 376.877% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | 11462.827% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | -57427.965% |
| OKYO Pharma Limited | -15.74 Thousand USD | 551431.873% |
| Savara Inc. | -59.13 Million USD | 246.808% |
| Curis, Inc. | -45.13 Million USD | 292.321% |
| Daré Bioscience, Inc. | -30.7 Million USD | 382.761% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 671.464% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 1311.612% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 424.725% |
| BeiGene, Ltd. | -1.12 Billion USD | 107.719% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 632.55% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 120.162% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 196.095% |
| Erasca, Inc. | -121.31 Million USD | 171.562% |
| bluebird bio, Inc. | -167.16 Million USD | 151.933% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 2029.689% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 72.022% |
| DBV Technologies S.A. | -85.98 Million USD | 200.965% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 2029.689% |
| Moderna, Inc. | -3.28 Billion USD | 102.644% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 303.741% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 1637.04% |
| Molecular Templates, Inc. | 1.43 Million USD | -5970.769% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 245.044% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 126.609% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 163.325% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 283.279% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 162.439% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 142.17% |
| MacroGenics, Inc. | 2.01 Million USD | -4204.016% |
| RenovoRx, Inc. | -11.39 Million USD | 862.177% |
| Adicet Bio, Inc. | -136.53 Million USD | 163.582% |
| Prime Medicine, Inc. | -193.75 Million USD | 144.804% |
| Aditxt, Inc. | -25.45 Million USD | 441.001% |
| Adagene Inc. | -14.95 Million USD | 680.652% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 1287.563% |
| Quantum-Si incorporated | -91.8 Million USD | 194.562% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 87.814% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 31.349% |
| SciSparc Ltd. | -5.28 Million USD | 1743.544% |
| Vericel Corporation | 2.86 Million USD | -2931.145% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 91281.413% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 500.213% |
| Generation Bio Co. | -133.3 Million USD | 165.125% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 204.555% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 200.917% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 138.17% |
| Invivyd, Inc. | -196.61 Million USD | 144.153% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 123.202% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 1035.999% |
| Spero Therapeutics, Inc. | 27.15 Million USD | -219.702% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 944.064% |
| 2seventy bio, Inc. | -206.41 Million USD | 142.056% |
| ADMA Biologics, Inc. | 5.12 Million USD | -1595.547% |
| Clene Inc. | -43.24 Million USD | 300.763% |
| Capricor Therapeutics, Inc. | -23 Million USD | 477.296% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 279.079% |
| GeoVax Labs, Inc. | -26.66 Million USD | 425.519% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 128.979% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 336.356% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | -268.269% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | -1667.973% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 367.262% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 154.804% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 112.686% |
| Evaxion Biotech A/S | -21.4 Million USD | 505.607% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 230.711% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 139.883% |
| Trevena, Inc. | -35.28 Million USD | 346.01% |
| Surrozen, Inc. | -41.13 Million USD | 311.062% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 209.071% |
| Cingulate Inc. | -22.95 Million USD | 478.232% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 1263.544% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 332.846% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 1155.289% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 184.888% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 227.99% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 248.722% |
| Clearmind Medicine Inc. | -8.71 Million USD | 1096.618% |
| Kronos Bio, Inc. | -121.83 Million USD | 171.257% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 216.774% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 3655.808% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 186.1% |
| Statera Biopharma, Inc. | 38.93 Million USD | -122.967% |
| ImmunityBio, Inc. | -436.18 Million USD | 119.903% |
| Korro Bio, Inc. | -80.9 Million USD | 207.302% |
| Kineta, Inc. | -15.71 Million USD | 652.45% |
| BioVie Inc. | -31.95 Million USD | 371.71% |
| Codexis, Inc. | -49.28 Million USD | 276.15% |
| Celularity Inc. | -183.94 Million USD | 147.194% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 139.191% |
| Celcuity Inc. | -58.3 Million USD | 248.88% |
| Virax Biolabs Group Limited | -6.6 Million USD | 1413.514% |
| Cibus, Inc. | -314.58 Million USD | 127.596% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 357.35% |
| IN8bio, Inc. | -28.5 Million USD | 404.561% |
| Kodiak Sciences Inc. | -259.02 Million USD | 133.515% |
| Annexon, Inc. | -141.57 Million USD | 161.319% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 177.098% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 235.23% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 410.542% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 137.743% |
| Eyenovia, Inc. | -24.1 Million USD | 460.126% |
| Puma Biotechnology, Inc. | 44.78 Million USD | -93.846% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 26893.827% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 217.625% |
| Arcellx, Inc. | -64.14 Million USD | 235.337% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 292.856% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 170.307% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 381.109% |
| Moolec Science SA | -52.07 Million USD | 266.704% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 268.221% |
| Geron Corporation | -174.78 Million USD | 149.669% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 314.791% |
| Royalty Pharma plc | 1.88 Billion USD | 95.4% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 172.59% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 1031.034% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 518.558% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 152.271% |
| Humacyte, Inc. | -96.45 Million USD | 190.0% |
| Structure Therapeutics Inc. | -102.45 Million USD | 184.729% |
| 89bio, Inc. | -134.46 Million USD | 164.562% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 210.063% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | -2042.448% |
| Genelux Corporation | -24.16 Million USD | 459.247% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 356.84% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 153.108% |
| Notable Labs, Ltd. | -14.4 Million USD | 702.861% |
| Liquidia Corporation | -70.05 Million USD | 223.927% |
| Mustang Bio, Inc. | -48.06 Million USD | 280.621% |
| Immunovant, Inc. | -269.97 Million USD | 132.155% |
| Quantum-Si incorporated | -91.8 Million USD | 194.562% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 222.295% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 549.617% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 185.1% |
| Acasti Pharma Inc. | -11.3 Million USD | 868.18% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 490.109% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 666.255% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 141.238% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 2132.905% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 646.675% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 401.682% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 334.437% |
| PepGen Inc. | -83.58 Million USD | 203.864% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 394.238% |
| United Therapeutics Corporation | 1.38 Billion USD | 93.74% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 479.141% |
| Solid Biosciences Inc. | -93.43 Million USD | 192.913% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 1919.296% |
| Immuneering Corporation | -58.06 Million USD | 249.519% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -2706853.539% |
| Silo Pharma, Inc. | -3.62 Million USD | 2494.012% |
| Belite Bio, Inc | -31.52 Million USD | 375.34% |
| XOMA Corporation | -39.36 Million USD | 320.548% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 228.711% |
| Bionomics Limited | -9.83 Million USD | 982.505% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 203.366% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 350.858% |
| uniQure N.V. | -253.1 Million USD | 134.299% |
| Cassava Sciences, Inc. | -95.68 Million USD | 190.725% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 1287.563% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 167.034% |
| Forte Biosciences, Inc. | -32.47 Million USD | 367.303% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 1178.347% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 407.637% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 26893.827% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 879.212% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 645.953% |
| Altimmune, Inc. | -87.93 Million USD | 198.723% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 194.28% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 350.858% |
| Compugen Ltd. | -12.51 Million USD | 793.608% |
| Peak Bio, Inc. | -1356.23 USD | 6401079.185% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 278.633% |
| Benitec Biopharma Inc. | -22.49 Million USD | 486.003% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 135.828% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 404.145% |
| Zura Bio Limited | -60.56 Million USD | 243.342% |
| PolyPid Ltd. | -20.26 Million USD | 528.426% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 656.024% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 404.145% |
| Instil Bio, Inc. | -146.12 Million USD | 159.411% |
| argenx SE | -216.02 Million USD | 140.186% |
| Immunome, Inc. | -28.27 Million USD | 407.071% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 279.094% |
| Verona Pharma plc | -52.46 Million USD | 265.458% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 191.601% |
| Shattuck Labs, Inc. | -87.61 Million USD | 199.083% |
| CervoMed Inc. | -2.17 Million USD | 4097.101% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 171.015% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 783.936% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 280.205% |
| Moolec Science SA | -52.07 Million USD | 266.704% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 606.488% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 166.578% |
| AnaptysBio, Inc. | -143.16 Million USD | 160.638% |
| Design Therapeutics, Inc. | -66.32 Million USD | 230.889% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 207.193% |
| NeurAxis, Inc. | -6.66 Million USD | 1402.604% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 329.966% |
| Lumos Pharma, Inc. | -36.57 Million USD | 337.386% |
| Achilles Therapeutics plc | -70.44 Million USD | 223.239% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 191.601% |
| 180 Life Sciences Corp. | -22.13 Million USD | 492.211% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | -1389.249% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 3655.808% |
| Nutriband Inc. | -5.12 Million USD | 1794.959% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 179.101% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 256.61% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 271.735% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 232.99% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 260.436% |
| Palisade Bio, Inc. | -12.28 Million USD | 806.881% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 291.317% |
| Beam Therapeutics Inc. | -156.47 Million USD | 155.48% |
| Neurogene Inc. | -52.28 Million USD | 266.033% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 163.603% |
| AEON Biopharma, Inc. | -48.36 Million USD | 279.508% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 193.328% |
| Sesen Bio, Inc. | -50.84 Million USD | 270.755% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 205.956% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 802.93% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 120.31% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 182.523% |
| Athira Pharma, Inc. | -116.7 Million USD | 174.387% |
| Vaccinex, Inc. | -19.74 Million USD | 539.599% |
| HCW Biologics Inc. | -23.57 Million USD | 468.221% |
| XOMA Corporation | -39.36 Million USD | 320.548% |
| Nektar Therapeutics | -243.1 Million USD | 135.709% |
| Arvinas, Inc. | -394.8 Million USD | 121.989% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -45903.837% |
| Merus N.V. | -149.2 Million USD | 158.182% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 192.857% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 377.71% |
| Rezolute, Inc. | -68.42 Million USD | 226.875% |
| Clene Inc. | -43.24 Million USD | 300.763% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 662.903% |
| BeyondSpring Inc. | -21.54 Million USD | 503.027% |
| Synlogic, Inc. | -55.16 Million USD | 257.379% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 818.464% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 915.749% |
| Peak Bio, Inc. | -1356.23 USD | 6401079.185% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 367.402% |
| Krystal Biotech, Inc. | 17.9 Million USD | -384.875% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 173.307% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 125.432% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 1984.582% |
| MannKind Corporation | 15.12 Million USD | -473.812% |
| Ikena Oncology, Inc. | -74.39 Million USD | 216.688% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 789.367% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | -327.077% |
| Gossamer Bio, Inc. | -172.15 Million USD | 150.428% |
| CohBar, Inc. | -12.06 Million USD | 819.491% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 440.319% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 389.132% |
| Legend Biotech Corporation | -477.87 Million USD | 118.166% |
| Mural Oncology plc | -192.72 Million USD | 145.046% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 176.115% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 637.693% |
| Disc Medicine, Inc. | -91.02 Million USD | 195.372% |
| Champions Oncology, Inc. | -5.05 Million USD | 1817.689% |
| REGENXBIO Inc. | -239.46 Million USD | 136.253% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 909.95% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 255.7% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 323.925% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 176.957% |
| Vaxart, Inc. | -74.72 Million USD | 216.178% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 346.567% |
| Cellectis S.A. | -98.09 Million USD | 188.498% |
| Longeveron Inc. | -20.06 Million USD | 532.762% |
| Repare Therapeutics Inc. | -114.27 Million USD | 175.969% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 119.766% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 216.04% |
| Revolution Medicines, Inc. | -430.58 Million USD | 120.162% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 1480.378% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 381.958% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 216.386% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | -1670.589% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 891.719% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 98.115% |
| Denali Therapeutics Inc. | -179.97 Million USD | 148.236% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 91281.413% |
| Veru Inc. | -89.97 Million USD | 196.484% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 422.985% |
| Cingulate Inc. | -22.95 Million USD | 478.232% |
| Passage Bio, Inc. | -98.34 Million USD | 188.277% |
| Context Therapeutics Inc. | -25.06 Million USD | 446.409% |
| Exicure, Inc. | -15.53 Million USD | 658.672% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 142.129% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 334.779% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 1555.943% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 151.531% |
| Nuvalent, Inc. | -149.49 Million USD | 158.071% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 1167.481% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 201.069% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 387.667% |
| OmniAb, Inc. | -49.73 Million USD | 274.563% |
| Anew Medical, Inc. | -1.3 Million USD | 6773.534% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 802.135% |
| Lipocine Inc. | -16.32 Million USD | 631.849% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 230.211% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 216.835% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 327.655% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 322.515% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 491.345% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 115.927% |
| Ocugen, Inc. | -64.82 Million USD | 233.913% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 193.78% |
| Q32 Bio Inc. | -86.5 Million USD | 200.358% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 612.861% |
| Alumis Inc. Common Stock | -156.89 Million USD | 155.333% |
| Equillium, Inc. | -12.13 Million USD | 815.208% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 248.468% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 1198.42% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 560.273% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 285.925% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 181.632% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 585.347% |
| Dominari Holdings Inc. | -22.44 Million USD | 486.863% |
| Edesa Biotech, Inc. | -8.19 Million USD | 1159.957% |
| vTv Therapeutics Inc. | -25.41 Million USD | 441.618% |
| Bio-Techne Corporation | 326.66 Million USD | 73.425% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 122.557% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 59.882% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 166.214% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 331.925% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 157.453% |
| Nkarta, Inc. | -120.48 Million USD | 172.055% |
| BioCardia, Inc. | -11.56 Million USD | 850.969% |
| Iterum Therapeutics plc | -34.58 Million USD | 351.047% |